Get the Stockscreener App
2.88
5.49%
0.15
Aclaris Therapeutics Inc stock is traded at $2.88, with a volume of 1.27M.
It is up +5.49% in the last 24 hours and up +33.95% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$2.73
Open:
$2.73
24h Volume:
1.27M
Relative Volume:
1.07
Market Cap:
$312.03M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-5.5385
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
+17.07%
1M Performance:
+33.95%
6M Performance:
+128.57%
1Y Performance:
-20.66%
1-Day Range:
$2.70
$2.90
1-Week Range:
$2.342
$2.90
52-Week Range:
$1.05
$4.24
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.88 | 295.78M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Can Aclaris Therapeutics Inc. stock beat analyst upgrades - BỘ NỘI VỤ
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Top investors say Aclaris Therapeutics Inc (ACRS) ticks everything they need - Setenews
Why Aclaris Therapeutics Inc. (8AT) stock attracts HNW investors - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock bottoming after sell offMarket Risk Analysis & Growth Focused Entry Reports - newser.com
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks - Yahoo Finance
How Aclaris Therapeutics Inc. stock benefits from tech adoptionNew Guidance & Smart Money Movement Alerts - newser.com
What hedge fund moves indicate for Aclaris Therapeutics Inc. (8AT) stockTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buyPortfolio Performance Report & Entry Point Confirmation Signals - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch ticker2025 Key Highlights & High Return Stock Watch Alerts - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergers2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a buy for dividend portfoliosLayoff News & Fast Momentum Entry Tips - newser.com
How cyclical is Aclaris Therapeutics Inc. (8AT) stock compared to rivalsPortfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Can Aclaris Therapeutics Inc. stock deliver strong Q4 earnings2025 Market Sentiment & Weekly Watchlist for Hot Stocks - newser.com
What high frequency data says about Aclaris Therapeutics Inc.2025 Market Outlook & Safe Entry Momentum Stock Tips - newser.com
Aclaris Therapeutics at Jefferies Conference: Strategic Expansion in Biopharma By Investing.com - Investing.com Canada
It is Poised to be a Bull Market for Aclaris Therapeutics Inc (ACRS) - Setenews
Will Aclaris Therapeutics Inc. stock deliver shareholder value2025 Dividend Review & Weekly Setup with ROI Potential - newser.com
Why Aclaris Therapeutics Inc. (8AT) stock gets analyst attention2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
Is Aclaris Therapeutics Inc. stock trading at a premium valuationWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Will Aclaris Therapeutics Inc. benefit from macro trendsEarnings Summary Report & Community Trade Idea Sharing - newser.com
Key resistance and support levels for Aclaris Therapeutics Inc.2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
How Aclaris Therapeutics Inc. stock trades before earningsAnalyst Upgrade & Weekly Return Optimization Plans - newser.com
Statistical indicators supporting Aclaris Therapeutics Inc.’s strengthEarnings Growth Summary & Expert Curated Trade Setup Alerts - newser.com
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MSN
Risk adjusted return profile for Aclaris Therapeutics Inc. analyzedJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.76%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):